Lupin Limited announced the launch of Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (USFDA).

Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc.

Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US (IQVIA MAT February 2024).